Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
1. Libtayo plus chemotherapy shows 19.4% five-year overall survival rate. 2. Significant efficacy in squamous NSCLC, 22.3-month median OS reported. 3. Results presented at IASLC 2025 indicate durable survival benefits. 4. Combination therapy outperformed chemotherapy alone in multiple metrics. 5. Libtayo is crucial in Regeneron's extensive cancer pipeline.